| Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.J Heart Lung Transplant | PMID 34353714无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study.Headache | PMID 34374086PMC8597120 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.Ann Oncol | PMID 34384882无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 34388360无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.Cancer Immunol Res | PMID 34389558PMC9414280 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.Lung Cancer | PMID 34403911无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Combination of body mass index and albumin predicts the survival in metastatic castration-resistant prostate cancer patients treated with abiraterone: A post hoc analysis of two randomized trials.Cancer Med | PMID 34414685PMC8495267 | 2021-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.Eur J Cancer | PMID 34418665无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The impact of induction chemotherapy on long-term quality of life in patients with locoregionally advanced nasopharyngeal carcinoma: Outcomes from a randomised phase 3 trial.Oral Oncol | PMID 34425533无 PMCID | 2021-Oct | 0.85 | This is a randomized phase 3 trial in oncology with a drug intervention (induction chemotherapy), but the primary endpoint of the report is quality of life, not a time-to-event efficacy outcome. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort. | 待处理 |
| Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study.Int J Infect Dis | PMID 34428542PMC8379820 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).Eur J Cancer | PMID 34450552无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| A prospective Phase III trial evaluating patient self-reported pain and cosmesis in accelerated partial breast irradiation utilizing 3-D versus intensity-modulated radiotherapy.Cancer Med | PMID 34469056PMC8525102 | 2021-Oct | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial.Adv Ther | PMID 34471992PMC8478739 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of the Efficacy and Safety of Ketoprofen Plaster and Diclofenac Plaster for Osteoarthritis-Related Knee Pain: A Multicenter, Randomized, Active-Controlled, Open-Label, Parallel-Group, Phase III Clinical Trial.Clin Ther | PMID 34479761无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.Br J Cancer | PMID 34480096PMC8548517 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.Nat Med | PMID 34480127PMC8516650 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial.Radiother Oncol | PMID 34480960无 PMCID | 2021-Oct | 0.95 | The record reports a secondary, quality-of-life endpoint from a definitive randomized phase III trial, but does not include the survival, progression, recurrence, death, hazard, or time-to-event outcomes required for inclusion in this Kaplan-Meier digitization cohort. | 待处理 |
| Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study.Lung Cancer | PMID 34482102无 PMCID | 2021-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Cancer Antigen 15-3/Mucin 1 Levels in CCTG MA.32: A Breast Cancer Randomized Trial of Metformin vs Placebo.JNCI Cancer Spectr | PMID 34485814PMC8410139 | 2021-Oct | 0.90 | The record describes a secondary analysis of a biomarker endpoint (CA 15-3) from a Phase III randomized trial. While the trial itself meets the oncology, human, randomized, Phase III, and drug intervention criteria, this specific report does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it is not eligible for the Kaplan-Meier digitization cohort. | 待处理 |
| A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension.Clin Ther | PMID 34503866无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.Adv Ther | PMID 34523074PMC8478753 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.Lancet Oncol | PMID 34529931无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).Adv Ther | PMID 34537926PMC8478768 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol | PMID 34543613无 PMCID | 2021-Oct | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.Cancer Med | PMID 34549539PMC8525125 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache.Headache | PMID 34551130PMC9291601 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.Breast Cancer Res Treat | PMID 34553296PMC8505315 | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial.Respir Med | PMID 34564020无 PMCID | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update.ESMO Open | PMID 34607285PMC8493593 | 2021-Oct | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33).Int J Gynecol Cancer | PMID 34607820无 PMCID | 2021-Oct | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies.BMJ Open Diabetes Res Care | PMID 34620618PMC8499286 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trial-EPOC 2 (JFMC49-1601-C5).ESMO Open | PMID 34626918PMC8511839 | 2021-Oct | 0.95 | While the record is from a definitive Phase III randomized oncology trial, the primary outcomes assessed (incidence of oral mucositis, nutritional changes, treatment completion rate) are adverse event mitigation and supportive care metrics, not the specified survival, progression, recurrence, death, hazard, or time-to-event efficacy outcomes required for inclusion in the cohort. | 待处理 |
| Has the time come for routine use of PET/CT for guiding treatment of biochemical recurrence after radical prostatectomy? RE: JaniAB, et al. 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial. Lancet. 2021 May 22;55:1895-1904.Scand J Urol | PMID 34633894无 PMCID | 2021-Oct | 0.45 | The record describes a Phase 2/3 randomized controlled trial for prostate cancer, meeting basic oncology, human, randomized, and phase criteria. However, the abstract and metadata do not explicitly mention a time-to-event endpoint (e.g., OS, PFS, DFS, Kaplan-Meier, HR) or a drug intervention. The intervention is PET/CT imaging to guide salvage radiotherapy, not a drug. Without clear evidence of a drug-containing arm and a time-to-event primary/key secondary endpoint, eligibility cannot be confirmed. | 待处理 |
| Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.Eur Respir J | PMID 34266940PMC8551561 | 2021-Oct | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.N Engl J Med | PMID 34587385无 PMCID | 2021-Sep-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Use of routinely collected health data in randomised clinical trials: comparison of trial-specific death data in the BOSS trial with NHS Digital data.Trials | PMID 34565428PMC8474902 | 2021-Sep-26 | 0.90 | The record describes a Phase III randomized trial in human oncology (oesophageal neoplasms) with an original result report and a primary time-to-event endpoint (overall survival, analyzed with Kaplan-Meier). However, the intervention is endoscopic surveillance (a procedure), not a drug-containing intervention, which is a required criterion. | 待处理 |
| Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial.Arthritis Res Ther | PMID 34563243PMC8464121 | 2021-Sep-25 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.N Engl J Med | PMID 34192426PMC8262625 | 2021-Sep-23 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med | PMID 34551229无 PMCID | 2021-Sep-23 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The Immunogenicity and Safety Profile for KM-248, a Combined Measles, Mumps, and Rubella Vaccine, and Its Noninferiority to the Measles Vaccine in Healthy Japanese Children: a Phase 3 Randomized Multicenter Single-Blind Clinical Trial.Jpn J Infect Dis | PMID 33518626无 PMCID | 2021-Sep-22 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Decentralized facility financing versus performance-based payments in primary health care: a large-scale randomized controlled trial in Nigeria.BMC Med | PMID 34544415PMC8452448 | 2021-Sep-21 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.J Clin Oncol | PMID 34185551PMC8445562 | 2021-Sep-20 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.Lancet | PMID 34469767无 PMCID | 2021-Sep-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.J Headache Pain | PMID 34537006PMC8449906 | 2021-Sep-18 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.N Engl J Med | PMID 34161051PMC8446332 | 2021-Sep-16 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children.N Engl J Med | PMID 34525285PMC8202713 | 2021-Sep-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety, feasibility and efficacy of metformin and sitagliptin in patients with a TIA or minor ischaemic stroke and impaired glucose tolerance.BMJ Open | PMID 34531203PMC8449977 | 2021-Sep-16 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study.Chin Med J (Engl) | PMID 35194005PMC8869628 | 2021-Sep-16 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Efficacy and Safety of Single Oral Dosing of Secnidazole for Trichomoniasis in Women: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Delayed-Treatment Study.Clin Infect Dis | PMID 33768237PMC8442793 | 2021-Sep-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh.Vaccine | PMID 34426025无 PMCID | 2021-Sep-15 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |